Ventyx Biosciences (VTYX) had the highest return between January 18, 2024 and February 27, 2024 by a US stock in the Pharmaceuticals Industry, returning 186.7%.
| ASSET | DATE | % RETURN |
|---|---|---|
Ventyx Biosciences (VTYX) | 1/18/2024 - 2/27/2024 | 186.73% |
Ocular Therapeutix (OCUL) | 1/18/2024 - 2/27/2024 | 138.55% |
Trevi Therapeutics (TRVI) | 1/18/2024 - 2/27/2024 | 102.19% |
Relmada Therapeutics (RLMD) | 1/18/2024 - 2/27/2024 | 79.15% |
Tvardi Therapeutics (TVRD) | 1/18/2024 - 2/27/2024 | 75.19% |
Tarsus Pharmaceuticals (TARS) | 1/18/2024 - 2/27/2024 | 71.94% |
Talphera (TLPH) | 1/18/2024 - 2/27/2024 | 71.25% |
Oramed Pharmaceuticals (ORMP) | 1/18/2024 - 2/27/2024 | 61.99% |
Enliven Therapeutics (ELVN) | 1/18/2024 - 2/27/2024 | 56.88% |
Nektar Therapeutics (NKTR) | 1/18/2024 - 2/27/2024 | 53.06% |
Milestone Pharmaceuticals (MIST) | 1/18/2024 - 2/27/2024 | 42.86% |
Grace Therapeutics (GRCE) | 1/18/2024 - 2/27/2024 | 40.51% |
Terns Pharmaceuticals (TERN) | 1/18/2024 - 2/27/2024 | 38.96% |
Fulcrum Therapeutics (FULC) | 1/18/2024 - 2/27/2024 | 38.69% |
Durect (DRRX) | 1/18/2024 - 2/27/2024 | 38.21% |
Titan Pharmaceuticals (TTNP) | 1/18/2024 - 2/27/2024 | 37.24% |
Scilex (SCLX) | 1/18/2024 - 2/27/2024 | 35.88% |
Phathom Pharmaceuticals (PHAT) | 1/18/2024 - 2/27/2024 | 33.91% |
Arvinas (ARVN) | 1/18/2024 - 2/27/2024 | 31.61% |
Eyepoint Pharmaceuticals (EYPT) | 1/18/2024 - 2/27/2024 | 30.2% |
Neumora Therapeutics (NMRA) | 1/18/2024 - 2/27/2024 | 30.13% |
Atea Pharmaceuticals (AVIR) | 1/18/2024 - 2/27/2024 | 28.45% |
Telomir Pharmaceuticals, Inc Common Stock (TELO) | 1/18/2024 - 2/27/2024 | 27.86% |
Amylyx Pharmaceuticals (AMLX) | 1/18/2024 - 2/27/2024 | 25.25% |
Eli Lilly and (LLY) | 1/18/2024 - 2/27/2024 | 23.35% |
